The Impact of Long-acting Injectable HIV Treatments on Public Health – Dr Kelly Gebo episode artwork

EPISODE · May 5, 2026 · 26 MIN

The Impact of Long-acting Injectable HIV Treatments on Public Health – Dr Kelly Gebo

from Going anti-Viral · host Going Anti-Viral

In episode 76 of Going anti-Viral, Dr Kelly Gebo joins host Dr Michael Saag to discuss the impact of long-acting injectable HIV treatments on public health. Dr Gebo is Dean of the Milken Institute School of Public Health at the George Washington University. An infectious disease physician-scientist, educator, and accomplished academic leader, Dr Gebo’s work focuses on health equity, access to care, and outcomes for people affected by infectious diseases such as HIV, COVID-19, and Mpox. Dr Gebo and Dr Saag discuss the current state of HIV epidemiology, the promise of long-acting injectables, and strategies to improve access and prevention efforts. Dr Saag and Dr Gebo also emphasize that advocacy is needed to expand access to long-acting injectable HIV treatments to reach at-risk populations.0:00 – Introduction 1:30 – Current epidemiology of HIV: a global and US perspective3:25 – Barriers to HIV screening and treatment6:27 – Exploring PrEP and long-acting injectables8:56 – Reaching at-risk populations for HIV prevention11:33 – Insurance coverage and access to HIV prevention13:59 – The role of primary care in HIV prevention16:27 – Advocacy for policy changes in HIV prevention23:53 – Implementation science and future directionsResources: The George Washington University Milken Institute School of Public Healthhttps://publichealth.gwu.edu/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email [email protected] to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

Episode metadata supplied by the publisher feed · Published May 5, 2026

Embed this episode

In episode 76 of Going anti-Viral, Dr Kelly Gebo joins host Dr Michael Saag to discuss the impact of long-acting injectable HIV treatments on public health. Dr Gebo is Dean of the Milken Institute School of Public Health at the George Washington University. An infectious disease physician-scientist, educator, and accomplished academic leader, Dr Gebo’s work focuses on health equity, access to care, and outcomes for people affected by infectious diseases such as HIV, COVID-19, and Mpox. Dr Geb...

Distinct summary based on available episode metadata or transcript content.

Ready to play

The Impact of Long-acting Injectable HIV Treatments on Public Health – Dr Kelly Gebo

0:00 26:43

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Going anti-Viral?

This episode is 26 minutes long.

When was this Going anti-Viral episode published?

This episode was published on May 5, 2026.

Can I download this Going anti-Viral episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!